Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study.
OBJECTIVE
To compare the efficacy and tolerability of tranylcypromine vs. lamotrigine in bipolar depression not responding to conventional antidepressants.


METHODS
Bipolar depressed patients received open randomized treatment with tranylcypromine or lamotrigine as add-on to a mood stabilizer during 10 weeks. In a second treatment phase, non-responding patients could receive the opposite drug. Outcome criteria were response (measured with CGI-BP and IDS-C), switch into mania, and completion of the study.


RESULTS
Only 20 of 70 planned patients were randomized, due to problems with recruitment, and 19 patients received any medication. During the first treatment phase 5/8 patients (62.5%) responded to tranylcypromine without switch into mania, compared with 4/11 patients (36.4%) on lamotrigine with two switches (statistically not significant). Over both treatment phases, 8/10 patients (80%) receiving tranylcypromine completed the study vs. 5/13 (38.5%) on lamotrigine (likelihood 0.02).


CONCLUSIONS
There still appears to be a role for tranylcypromine in the treatment of refractory bipolar depression. Larger controlled studies are demanded.
Nolen
W A
WA
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. w.a.nolen@med.umcg.nl
Kupka
R W
RW
Hellemann
G
G
Frye
M A
MA
Altshuler
L L
LL
Leverich
G S
GS
Suppes
T
T
Keck
P E
PE
McElroy
S
S
Grunze
H
H
Mintz
J
J
Post
R M
RM
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015982:Bias; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D018579:Patient Selection; D010552:Personality Assessment; D018401:Sample Size; D014191:Tranylcypromine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D000927:Anticonvulsants; D000928:Antidepressive Agents; D014227:Triazines; D014191:Tranylcypromine; D000077213:Lamotrigine